1 Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence. Cancers (Basel). 2020;12(3):378.
2 Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chávez A, Keegan N, Khamashta MA, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6(1):38.
3 Sznol M, Ferrucci PF, Hogg D, Atkins MB, Wolter P, Guidoboni M, et al. Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. J Clin Oncol. 2017;35(34):3815–22.
4 Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer. N Engl J Med. 2012;366(26):2443–54.
5 Paraneoplastic and autoimmune encephalitis – UpToDate [Internet]. [cited 2021 Jan 12]. Available from: https://www.uptodate.com/contents/paraneoplastic-and-autoimmune-encephalitis?search=anti-hu&source=search_result&selectedTitle=2~22&usage_type=default&display_rank=2.
6 Drekolias D, Gadela NV, Jacob J. Paraneoplastic Confusion: A Case of Anti-Hu Encephalitis. Cureus. 2020;12(7):e9205.
7 Dalakas MC. Neurological complications of immune checkpoint inhibitors: what happens when you «take the brakes off» the immune system. Ther Adv Neurol Disord. 2018;11:1756286418799864.
8 Larkin J, Chmielowski B, Lao CD, Hodi FS, Sharfman W, Weber J, et al. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis. Oncologist. 2017;22(6):709–18.
9 Kao JC, Liao B, Markovic SN, Klein CJ, Naddaf E, Staff NP, et al. Neurological Complications Associated With Anti–Programmed Death 1 (PD-1) Antibodies. JAMA Neurol. 2017;74(10):1216–22.
10 Niki M, Nakaya A, Kurata T, Nakahama K, Yoshioka H, Kaneda T, et al. Pembrolizumab-induced autoimmune encephalitis in a patient with advanced non-small cell lung cancer: A case report. Mol Clin Oncol. 2019;10(2):267–9.
11 Salam S, Lavin T, Turan A. Limbic encephalitis following immunotherapy against metastatic malignant melanoma. BMJ Case Rep. 2016;2016:bcr2016215012.
12 Arakawa M, Yamazaki M, Toda Y, Saito R, Ozawa A, Kosaihira S, et al. Atezolizumab-induced encephalitis in metastatic lung cancer: a case report and literature review. eNeurologicalSci. 2019;14:49–50.
13 Laserna A, Tummala S, Patel N, El Hamouda DEM, Gutiérrez C. Atezolizumab-related encephalitis in the intensive care unit: Case report and review of the literature. SAGE Open Med Case Rep. 2018;6:2050313X18792422.
14 Levine JJ, Somer RA, Hosoya H, Squillante C. Atezolizumab-induced Encephalitis in Metastatic Bladder Cancer: A Case Report and Review of the Literature. Clin Genitourin Cancer. 2017;15(5):e847–e849.
15 Astaras C, de Micheli R, Moura B, Hundsberger T, Hottinger AF. Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management. Curr Neurol Neurosci Rep. 2018;18(1):3.
16. Oyanguren B, Sánchez V, González FJ, de Felipe A, Esteban L, López-Sendón JL, et al. Limbic encephalitis: a clinical-radiological comparison between herpetic and autoimmune etiologies. Eur J Neurol. 2013;20(12):1566–70.
17 Santini FC, Rizvi H, Wilkins O, van Voorthuysen M, Panora E, Halpenny D, et al. Safety of retreatment with immunotherapy after immune-related toxicity in patients with lung cancers treated with anti-PD(L)-1 therapy. J Clin Oncol. 2017;35(15_suppl):9012.